News

Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma to Present Phase IA Data From Anti-Cancer Compound at the AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

BOULDER, Colo., Nov. 8 /PRNewswire-FirstCall/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that a scientific poster on its anti-cancer compound, ARRY-142886 (AZD6244), will be presented at the AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics in Philadelphia, Pennsylvania.

Poster: "A First in Human Dose-Ranging Study to Assess the Pharmacokinetics, Pharmacodynamics and Toxicities of the MEK Inhibitor, ARRY-142886 (AZD6244) in Patients with Advanced Solid Malignancies"
Date: Thursday, November 17, 2005
Time: 12:30 - 2:30 pm and 5:30 - 7:30 pm Eastern Time
Location: Pennsylvania Convention Center, Philadelphia, Pennsylvania

In addition, the following posters will be presented:

Poster: "In Vivo Anti-Tumor Activity of ARRY-334543, a Small Molecule Inhibitor of EGFR and ErbB-2"
Date: Tuesday, November 15, 2005
Time: 12:30 - 2:30 pm and 5:30 - 7:30 pm Eastern Time
Location: Pennsylvania Convention Center, Philadelphia, Pennsylvania

Poster: "Combination Studies In Vitro and In Vivo with gefitinib (IRESSA) and the MEK1/2 Inhibitor AZD6244 (ARRY-142886)"
Date: Tuesday, November 15, 2005
Time: 12:30 - 2:30 pm and 5:30 - 7:30 pm Eastern Time
Location: Pennsylvania Convention Center, Philadelphia, Pennsylvania

Poster: "4-(4-Bromo-2-fluorophenylamino)-1-methyl-pyridin-2(1H)ones: Potent and Selective MEK 1, 2 Inhibitors"
Date: Wednesday, November 16, 2005
Time: 12:30 - 2:30 pm and 5:30 - 7:30 pm Eastern Time
Location: Pennsylvania Convention Center, Philadelphia, Pennsylvania

A PDF of each poster will be available for viewing on Array's website at www.arraybiopharma.com on Monday, November 21.

About Array BioPharma:

Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of orally active drugs to address significant unmet medical needs. Our proprietary drug development pipeline is primarily focused on the treatment of cancer and inflammatory disease and includes several small molecule drug candidates that are designed to regulate targets in therapeutically important biologic pathways. In addition, leading pharmaceutical and biotechnology companies access our drug discovery technologies and expertise through collaborations to design, create, optimize and evaluate drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.

SOURCE Array BioPharma Inc.
11/08/2005
CONTACT: Tricia Haugeto of Array BioPharma Inc., +1-303-386-1193, thaugeto@arraybiopharma.com
Web site: http://www.arraybiopharma.com
(ARRY)